Brief: NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101

NRX Pharmaceuticals

26/10/2023 11:52

Oct 26 (Reuters) - NRX Pharmaceuticals Inc  NRXP.O :
    * NRX PHARMACEUTICALS ANNOUNCES FURTHER ALIGNMENT WITH FDA
ON
INITIATION OF REGISTRATIONAL TRIALS FOR NRX-101 IN THE TREATMENT
OF CHRONIC PAIN
    * NRX PHARMACEUTICALS INC - IND PRECLINICAL REQUIREMENTS ARE
CONSISTENT WITH STUDIES ALREADY IN PROGRESS TO SUPPORT TREATMENT
OF BIPOLAR DEPRESSION
    * NRX PHARMACEUTICALS INC: "STUDY MAY PROCEED" LETTER
RECEIVED
FROM FDA
    * NRX PHARMACEUTICALS:POTENTIAL TO START REGISTRATIONAL
STUDIES IN
2024 PENDING RECEIPT OF DATA FROM ALREADY-COMPLETED DOD-FUNDED
TRIAL OF D-CYCLOSERINE
    * NRX PHARMACEUTICALS INC - AWAITS RESULTS FROM
ALREADY-COMPLETED
DOD-FUNDED TRIAL OF D-CYCLOSERINE VERSUS. PLACEBO

Source text for Eikon:  ID:nPn2mcTQGa 
Further company coverage:  NRXP.O 

 ((Reuters.Briefs@thomsonreuters.com;))